Leptin tA Mouse, PEG
(a) Gel filtration analysis.
(b) Analysis by SDS-PAGE.
Description
The Mouse Leptin antagonist was mutated, resulting in L39A/D40A/F41A mutant.
The Mouse Leptin antagonist is bound to 20 kDa mono-PEG at N-terminus, resulting in 35.6 kDa. The Mouse Leptin triple anatagonist runs as a 48 kDa.
Leptin Antagonist Triple Mutant Mouse Recombinant was purified by proprietary chromatographic techniques.
Product Specs
This modified Mouse Leptin antagonist features the mutations L39A/D40A/F41A.
The molecule is conjugated to a 20 kDa mono-PEG molecule at the N-terminus, resulting in a total weight of 35.6 kDa. However, it appears as a 48 kDa band on gel electrophoresis.
The purification of Leptin Antagonist Triple Mutant Mouse Recombinant was achieved using proprietary chromatographic techniques.
To reconstitute the lyophilized Leptin Antagonist Triple Mutant Mouse Recombinant, it is recommended to dissolve it in sterile water or sterile 0.4% NaHCO3, adjusting the pH to 8-9. The initial reconstitution should be at a concentration no less than 100µg/ml. The solution can then be further diluted using other aqueous solutions as needed.
Repeated freeze-thaw cycles should be avoided.
(a) Gel filtration analysis.
(b) SDS-PAGE analysis.
This molecule effectively inhibits leptin-induced proliferation in BAF/3 cells that have been stably transfected with the long form of the human leptin receptor. While the in vitro activity of Leptin Antagonist Triple Mutant Mouse Recombinant is 5-6 fold lower compared to the non-pegylated antagonist, it demonstrates a significant weight gain effect in vivo (compared to the non-pegylated form), primarily due to increased food intake.
Product Science Overview
Leptin is a hormone predominantly made by adipose cells and enterocytes in the small intestine that helps to regulate energy balance by inhibiting hunger. It is often referred to as the “satiety hormone” or “fat hormone.” Leptin’s primary target is the hypothalamus in the brain where it inhibits appetite by counteracting the effects of neuropeptide Y, a potent feeding stimulant secreted by cells in the gut and in the hypothalamus.
The Leptin Antagonist Triple Mutant is a modified form of leptin designed to inhibit the action of natural leptin. This antagonist is particularly useful in research settings where scientists aim to study the effects of leptin inhibition on various physiological processes. The triple mutant refers to specific amino acid substitutions in the leptin protein, typically L39A, D40A, and F41A. These mutations significantly reduce the binding affinity of leptin to its receptor, thereby acting as an antagonist.
Pegylation is the process of attaching polyethylene glycol (PEG) chains to another molecule, in this case, the leptin antagonist. Pegylation is used to improve the pharmacokinetics of therapeutic proteins by increasing their solubility, stability, and half-life in the bloodstream. The pegylated form of the leptin antagonist is more stable and has a longer duration of action compared to its non-pegylated counterpart.
The term “mouse recombinant” indicates that the leptin antagonist is produced using recombinant DNA technology in a mouse model. This involves inserting the gene encoding the leptin antagonist into a host cell, which then produces the protein. The recombinant protein is then harvested and purified for use in research.
The Leptin Antagonist Triple Mutant Pegylated (Mouse Recombinant) is primarily used in research to study the role of leptin in various physiological and pathological processes. It is particularly useful in obesity research, where it helps to elucidate the mechanisms by which leptin regulates body weight and energy balance. By inhibiting leptin signaling, researchers can better understand the pathways involved in appetite regulation, energy expenditure, and fat storage.
